Research and Markets: The New Trends of Drug Discovery Outsourcing in China and India 2012

<0> Research and Markets: The New Trends of Drug Discovery Outsourcing in China and India 2012 </0>

<0> Research and MarketsLaura Wood, Senior ManagerU.S. Fax: 646-607-1907Fax (outside U.S.): +353-1-481-1716Sector: </0>

() has announced the addition of the report to their offering.

The report, The New Trends of Drug Discovery Outsourcing in China and India, published by JZMed, Inc, a world renowned market research firm specialized in pharmaceutical and biotechnology industries, has conducted so far the most complete and comprehensive comparisons between China and India in the drug discovery research service industry. It is designed to help readers gain a clear understanding of which country between China and India is better suitable for what type of discovery research projects and what different but successful discovery research outsourcing strategies global drug companies have been taking in each country.

The rises of China and India as two key emerging markets provide enormous opportunities to both multinational drug companies and professional outsourcing service providers. However, there are significant differences between these two countries, in particular in the areas related to drug R&D, which makes each country unique for certain types of outsourcing activities. Although multinational drug companies now could have more choices than ever before, China and India each actually play different roles in global pharma outsourcing industry in general and in drug discovery research service in specific.

The report is a must-read book to all global pharmaceutical, biotechnology, financial investment and outsourcing service companies that are interested in having a best position in either one of these two countries. It is also a valuable reference book to drug regulatory agencies and other government agencies that are involved in strategic planning for development of the pharmaceutical industry in their own countries.

Scope of the Report

Executive Summary

- China and India: The two key emerging players of global drug R&D outsourcing

- Current experiences of Chinese and Indian companies in innovative drug R&D

- The new trends of drug discovery outsourcing in China and India

- The new trends of preclinical and toxicology research outsourcing in China and India

- Analysis of best strategies for drug discovery outsourcing in China and India

Chapter One - China and India: The Two Key Emerging Players of Global Drug R&D Outsourcing

Chapter Two - Current Experiences of Chinese and Indian Companies in Innovative Drug R&D

Chapter Three - The New Trends of Drug Discovery Outsourcing in China and India

Chapter Four - The New Trends of Preclinical and Toxicology Research Outsourcing in China and India

Chapter Five - Analysis of Best Strategies for Drug Discovery Outsourcing in China and India

Appendix

List of Tables

List of Figures

List of Case Studies

For more information visit

Suggested Articles

The Pharma Lions shortlist for 2019 lives up to its name with just 31 entries making the cut. But it's still good news for the 12 drugmaker finalists.

Pharma companies filed suit Friday to block the new HHS rule that requires drugmakers to put list prices in TV ads.

Cannes Lions Health kicks off Monday, and attendees are looking for some breakouts—leading-edge tech, creativity and inspiration, for instance.